Table I-21US PREVALENCE COUNTS, INVASIVE CANCERS ONLY, JANUARY 1, 2005aUSING DIFFERENT TUMOR INCLUSION CRITERIAb

	5-Year Limited Duration			30-year Limited Duration			
Site/Sex	lst	lst Per Site	lst Per Site	lst	lst Per Site		
	Invasive	in Previous	in Previous	Invasive	in Previous		
	Tumor Ever ^c	30 Years ^d	5 Years ^e	Tumor Ever ^c	30 Years ^d		
All Sites	4,047,630	4,124,002	4,471,606	10,505,741	10,700,724		
Male	2,069,338	2,097,658	2,265,792	4,896,353	4,954,654		
Female	1,978,292	2,026,344	2,205,814	5,609,388	5,746,070		
Oral Cavity & Pharynx	86,675	99,393	102,699	223,620	245,611		
Male	58,447	66,437	68,409	144,387	157,204		
Female	28,228	32,956	34,290	79,233	88,407		
Esophagus	18,953	22,591	22,591	27,187	31,941		
Male	14,462	17,126	17,126	20,510	23,821		
Female	4,491	5,465	5,465	6,677	8,120		
Stomach	31,518	37,554	37,666	60,885	69,650		
Male	18,834	22,619	22,647	34,789	40,033		
Female	12,684	14,935	15,019	26,096	29,617		
Colon & Rectum	414,431	477,379	485,167	1,050,283	1,168,268		
Male	209,554	241,797	245,238	515,575	570,013		
Female	204,877	235,582	239,929	534,708	598,255		
Liver & Intrahep	15,981	18,086	18,086	21,259	23,745		
Male	11,073	12,473	12,473	14,023	15,605		
Female	4,908	5,613	5,613	7,236	8,140		
Pancreas	21,905	26,051	26,051	29,026	33,751		
Male	10,950	13,152	13,152	14,178	16,577		
Female	10,955	12,899	12,899	14,848	17,174		
Larynx	30,668	35,999	36,272	88,989	98,327		
Male	24,542	28,792	29,019	71,335	78,509		
Female	6,126	7,207	7,253	17,654	19,818		
Lung & Bronchus	206,013	255,746	260,876	348,273	417,553		
Male	99,962	125,160	127,386	165,661	198,810		
Female	106,051	130,586	133,490	182,612	218,743		
Melanoma of the Skin	221,975	247,168	256,223	677,773	725,006		
Male	116,685	132,017	137,768	333,977	360,601		
Female	105,290	115,151	118,455	343,796	364,405		
Breast Female	808,737	867,285	909,008	2,377,471	2,521,460		
Cervix Female	40,655	42,514	42,620	189,952	195,487		
Corpus & Uterus Female	145,463	163,808	163,843	511,115	554,123		
Ovary ^f Female	53,959	63,067	63,111	151,232	170,276		

US 2005 cancer prevalence counts are based on 2005 cancer prevalence proportions from the SEER 9 registries and 1/1/2005 US population estimates based on the average of 2004 and 2005 population estimates from the US Bureau of the Census.

(b) Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion: (c) First invasive tumor ever; (d) First invasive tumor for each cancer site diagnosed during the previous 30 years (1975-2004); (e) First invasive tumor for each cancer site diagnosed during the previous 5 years (2000-2004).
 For definitions (d) and (e) all sites is treated as a separate cancer "site".

Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 2000; Melanoma in 2001.

In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 30-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred more than 5 years prior to 1/1/2005. In method (d) the 1981 melanoma is counted for the melanoma and all sites 30-year limited

In method (d) the 1981 melanoma is counted for the melanoma and all sites 30-year limited duration prevalence. The 2000 breast cancer is counted for the breast 5-year and 30-year limited duration prevalence.

In method (e) the 2000 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 2001 melanoma is counted for 5-year limited duration prevalence for melanoma.

^f Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

а

Table I-21 - continuedUS PREVALENCE COUNTS, INVASIVE CANCERS ONLY, JANUARY 1, 2005aUSING DIFFERENT TUMOR INCLUSION CRITERIA^b

	5-Year Limited Duration			30-year Limited Duration			
Site/Sex	lst	lst Per Site	lst Per Site	lst	lst Per Site		
	Invasive	in Previous	in Previous	Invasive	in Previous		
	Tumor Ever [°]	30 Years ^d	5 Years ^e	Tumor Ever ^c	30 Years ^d		
Prostate Male	939,384	1,013,473	1,013,521	2,102,958	2,244,449		
Testis Male	39,561	40,196	40,664	165,843	167,969		
Urinary Bladder	187,611	229,342	232,628	500,529	575,400		
Male	140,466	171,744	174,234	370,894	424,832		
Female	47,145	57,598	58,394	129,635	150,568		
Kidney & Renal Pelvis	105,967	127,975	128,978	242,021	279,591		
Male	63,208	77,412	78,092	142,504	165,759		
Female	42,759	50,563	50,886	99,517	113,832		
Brain & Nervous System	40,067	41,895	42,078	105,744	108,660		
Male	21,582	22,580	22,690	56,701	58,150		
Female	18,485	19,315	19,388	49,043	50,510		
Thyroid	111,720	120,840	121,123	344,182	362,308		
Male	24,952	28,074	28,096	76,616	81,765		
Female	86,768	92,766	93,027	267,566	280,543		
Hodgkin Lymphoma	34,567	36,114	36,138	140,716	143,814		
Male	18,082	18,848	18,859	72,571	74,112		
Female	16,485	17,266	17,279	68,145	69,702		
Non-Hodgkin Lymphoma	173,017	198,936	200,239	389,438	430,711		
Male	89,995	104,311	104,889	201,376	222,211		
Female	83,022	94,625	95,350	188,062	208,500		
Myeloma	37,951	43,567	43,601	55,888	63,084		
Male	20,764	24,306	24,340	30,945	35,402		
Female	17,187	19,261	19,261	24,943	27,682		
Leukemia	91,507	103,055	103,168	213,808	231,461		
Male	52,959	59,875	59,932	120,855	131,096		
Female	38,548	43,180	43,236	92,953	100,365		
Acute Lymphocytic Leuk	14,454	14,746	14,746	52,633	53,040		
Male	8,169	8,268	8,268	28,919	29,056		
Female	6,285	6,478	6,478	23,714	23,984		
Childhood (0-19)	59,044	59,122	59,392	248,912	249,391		
Male	31,593	31,637	31,734	127,804	128,005		
Female	27,451	27,485	27,658	121,108	121,386		
Kaposi Sarcoma	6,456	6,920	6,920	20,669	21,698		
Male	5,958	6,317	6,317	19,259	20,131		
Female	498	603	603	1,410	1,567		
Mesothelioma	2,847	3,600	3,600	4,361	5,219		
Male	2,040	2,599	2,599	2,646	3,276		
Female	807	1,001	1,001	1,715	1,943		

US 2005 cancer prevalence counts are based on 2005 cancer prevalence proportions from the SEER 9 registries and 1/1/2005 US population estimates based on the average of 2004 and 2005 population estimates from the US Bureau of the Census.

(b) Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion: (c) First invasive tumor ever; (d) First invasive tumor for each cancer site diagnosed during the previous 30 years (1975-2004); (e) First invasive tumor for each cancer for definitions (d) and (e) all sites is treated as a separate cancer "site".

Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 2000; Melanoma in 2001.

In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 30-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred more than 5 years prior to 1/1/2005.

In method (d) the 1981 melanoma is counted for the melanoma and all sites 30-year limited duration prevalence. The 2000 breast cancer is counted for the breast 5-year and 30-year limited duration prevalence.

In method (e) the 2000 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 2001 melanoma is counted for 5-year limited duration prevalence for melanoma.

а

Table I-22 US COMPLETE PREVALENCE COUNTS, INVASIVE CANCERS ONLY, January 1, 2005^a

BY AGE AT PREVALENCE

	Age Specific								
Age at Prevalence	All Ages ^c	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70+
-1. /-									
Site/Sex									
All Sites Males	5,017,159	16,399	39,131	72,187	144,424	325,302	684,471	1,158,366	2,576,879
Females	6,081,291	14,148	39,131	78,183	213,178	325,302 591,903	1,084,176	1,295,883	2,576,879 2,770,913
Oral Cavity & Pharynx	154 150	0.0	455	1 250	2 2 2 5	14 200	24.000	20.166	<u> </u>
Males	154,159	22	457	1,378	3,285	14,388	34,829	39,166	60,632
Females	86,017	94	445	1,590	3,294	8,286	15,001	18,032	39,275
Esophagus									
Males	20,618	0	0	14	190	993	4,149	6,451	8,820
Females	6,790	0	12	24	39	245	870	1,475	4,126
Stomach									
Males	36,118	0	17	64	601	2,306	5,417	8,526	19,186
Females	27,093	17	23	133	452	1,835	3,582	4,955	16,095
Colon & Rectum									
Males	531,875	11	58	908	4,952	21,683	65,986	117,180	321,098
Females	563,408	0	92	1,021	4,786	19,725	55,223	95,601	386,961
Liver & Intrahep									
Males	14,098	318	426	302	385	1,286	4,581	3,125	3,676
Females	7,544	406	317	308	348	739	1,283	1,519	2,624
Pancreas									
Males	14,355	0	35	69	243	1,227	3,204	3,844	5,732
Females	15,090	0	62	115	368	1,335	2,493	3,533	7,183
Larynx									
Males	74,702	0	0	46	211	2,653	10,886	19,951	40,955
Females	18,394	0	0	46	186	1,184	2,730	5,061	9,186
Lung & Bronchus									
Males	172,426	22	88	267	1,144	6,635	23,556	50,032	90,682
Females	187,655	0	44	360	1,473	8,522	25,008	50,522	101,726
Melanoma of the Skin									
Males	349,414	70	796	4,912	16,062	46,512	78,727	81,518	120,817
Females	374,002	70	890	4,912	31,346	40,512 67,262	88,525	69,337	120,817
remates	5/4,002	/ 0	090	T0,T20	21,240	01,202	00,525	156,00	100,40/

US 2005 cancer prevalence counts are based on 2005 cancer prevalence proportions from the SEER 9 registries (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta) and 1/1/2005 US population estimates based on the average of 2004 and 2005 population estimates from the US Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person. Cases diagnosed more than 30 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et.

b al. 2000). С

Due to rounding, the sum of the age specific estimates may not equal the all ages estimate.

а

Table I-22 - continued US COMPLETE PREVALENCE COUNTS, INVASIVE CANCERS ONLY, January 1, 2005^a BY AGE AT PREVALENCE

	Age Specific								
Age at Prevalence	All Ages ^c	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70+
Site/Sex									
Breast									
Males	12,864	0	0	23	86	500	2,112	3,338	6,80
Females	2,477,847	0	70	2,367	35,542	205,803	485,718	597,083	1,151,26
Cervix									
Females	249,756	23	58	2,406	18,587	44,912	56,492	49,040	78,23
Corpus & Uterus, NOS									
Females	572,626	0	43	598	4,635	23,170	73,904	120,851	349,42
Dvary ^d									
Females	174,236	44	985	3,228	7,229	20,668	36,444	39,782	65,85
Prostate									
Males	2,106,499	22	69	93	286	16,233	179,722	532,480	1,377,59
Jrinary Bladder									
Males	384,294	39	139	619	2,498	12,873	40,736	85,424	241,96
Females	136,858	11	56	425	1,212	4,625	12,496	26,832	91,20
(idney & Renal Pelvis									
Males	148,837	1,493	2,452	2,268	4,063	13,380	29,131	38,394	57,65
Females	104,665	1,495	2,574	2,621	3,821	9,794	16,463	22,752	45,14
Hodgkin Lymphoma									
Males	80,386	127	2,071	8,803	16,282	22,142	17,052	8,546	5,36
Females	75,786	66	1,541	9,602	16,859	20,963	14,940	6,428	5,38
Ion-Hodgkin Lymphoma									
Males	207,821	585	3,464	6,304	11,912	25,726	40,865	46,986	71,9
Females	193,876	313	1,515	3,644	7,917	18,360	33,094	41,373	87,6
Iyeloma									
Males	31,066	0	0	40	550	2,132	6,299	9,490	12,5
Females	25,134	0	0	23	283	1,525	4,520	6,533	12,2
eukemia									
Males	123,731	6,018	11,203	9,962	8,677	10,545	16,300	21,846	39,1
Females	96,332	4,782	9,585	9,056	7,170	7,633	10,616	13,737	33,75
Acute Lymphocytic Leuk									
Males	30,765	4,979	9,818	7,749	4,881	1,772	722	528	31
Females	25,452	4,032	8,130	6,555	3,892	1,532	651	356	30

^a US 2005 cancer prevalence counts are based on 2005 cancer prevalence proportions from the SEER 9 registries (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta) and 1/1/2005 US population estimates based on the average of 2004 and 2005 population estimates from the US Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

Cases diagnosed more than 30 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

Due to rounding, the sum of the age specific estimates may not equal the all ages estimate.

d Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

С